Overview

Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections

Status:
Terminated

Trial end date:
2017-02-21

Target enrollment:

Participant gender:

Summary

SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in patients with wet age related macular degeneration who have incomplete response with routineranibizumab treatment.

Phase:

Phase 4

Details

Lead Sponsor:

St. Michael's Hospital, Toronto
Unity Health Toronto

Treatments:

Aflibercept
Ranibizumab